For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...

The data highlight the possibility of SGLT 1/2 inhibitors having protective effects beyond heart failure and diabetes.

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

It comes as a study found fewer than 18% of people in England have been treated with the most suitable blood sugar lowering ...

New figures show fewer than one in five people with the condition in England are on the best medication for them to manage ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, ...

Researchers have found in a new study that SGLT2 inhibitors may have disease-modifying effects in nonsevere aortic stenosis ...

The global Heart Failure Drugs Market is valued at $8.6 billion in 2024 and is projected to reach a value of $21.4 billion by 2035. This growth represents a Compound Annual Growth Rate (CAGR) of 12.1% ...